Bemcentinib is under clinical development by BerGenBio and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Bemcentinib’s likelihood of approval (LoA) and phase transition for Lung Adenocarcinoma took place on 19 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

In addition, the same event on 19 Dec 2022 increased Bemcentinib’s Phase Transition Success Rate (PTSR) for Non-Small Cell Lung Cancer.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Bemcentinib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Bemcentinib overview

Bemcentinib (BGB-324, R-428) is under development for the treatment of inflammatory Breast cancer, idiopathic pulmonary fibrosis, metastatic melanoma, relapsed/refractory acute myeloid leukaemia, myelodysplastic syndrome, non-small cell lung cancer including lung adenocarcinoma, malignant mesothelioma and pancreatic ductal adenocarcinoma, glioblastoma, nonalcoholic steatohepatitis (NASH), bladder cancer, renal cell carcinoma and coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is administered through oral route and acts by targeting Axl kinase. The drug candidate is a first-in-class selective AXL kinase inhibitor. The drug candidate is based on CellSelect Technology. It was also under development for chronic myelocytic leukemia, triple-negative breast cancer (TNBC) and liver fibrosis.

BerGenBio overview

BerGenBio focuses on the development of transformative drugs built on AXL receptor tyrosine kinase (AXL) inhibitors for the treatment of therapy-resistant cancers. Its key pipeline products include Bemcentinib (BGB324), Tilvestamab BGB149 and BGB601 (ADCT-601). Bemcentinib (BGB324) is an orally bioavailable and AXL inhibitor, which is used for the treatment of advanced non-small-cell lung cancer (NSCLC), high-risk myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and Covid – 19. Tilvestamab BGB149 is a functional blocking anti-AXL monoclonal antibody, which prevents AXL mediated cell signaling in cancer cell lines, illustrates anti-tumor efficacy and decreases cell migration and invasion. BGB601 is an antibody-drug conjugate, which is under Phase I trial. BerGenBio is headquartered in Bergen, Norway.

Quick View Bemcentinib LOA Data

Report Segments
  • Innovator
Drug Name
  • Bemcentinib
Administration Pathway
  • Oral
Therapeutic Areas
  • Gastrointestinal
  • Infectious Disease
  • Oncology
  • Respiratory
Key Developers
  • Sponsor Company: BerGenBio
  • Originator: Rigel Pharmaceuticals
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.